Etizolam in the treatment of generalized anxiety disorder: a controlled clinical trial.

Article Details

Citation
Copy to clipboard

Bertolino A, Mastucci E, Porro V, Corfiati L, Palermo M, Ecari U, Ceccarelli G

Etizolam in the treatment of generalized anxiety disorder: a controlled clinical trial.

J Int Med Res. 1989 Sep-Oct;17(5):455-60.

PubMed ID
2572494 [ View in PubMed
]
Abstract

A total of 45 patients with generalized anxiety disorder were treated twice daily for 2 weeks, on a double-blind basis, with 0.5 mg etizolam, 0.5 mg alprazolam or 3 mg bromazepam, and symptoms were assessed using Hamilton's rating scale for anxiety and Hamilton's rating scale for depression. Patients then received the same drug for a further 2 weeks, the drugs being given three times daily if a poor response was observed during the first 2 weeks. All drugs displayed equivalent anxiolytic activity after 2 weeks, but etizolam displayed a progressive increase in anxiolytic activity over 4 weeks of treatment. Etizolam also possessed a more marked antidepressant effect than did alprazolam or bromazepam. There were no differences in the tolerability of the three drugs.

DrugBank Data that Cites this Article

Drugs